Bristol-Myers, Infinity Pharma to evaluate Opdivo with IPI-549 in advanced solid tumors
Thursday, November 10, 2016
Bristol-Myers Squibb and infinity pharmaceuticals announce clinical collaboration to evaluate Opdivo (nivolumab) in combination with IPI-549 in advanced solid tumors.
Bristol-Myers Squibb - evaluation of IPI-549 as a monotherapy continuing, with combination portion of phase 1 study expected to begin this fall.
Bristol-Myers Squibb says study to evaluate potential of ipi-549 plus Opdivo to target immune-suppressive cells in tumor microenvironment.
Source : reuters.com
